LUCENTIS MARKET DYNAMICS: SIZE, DECLINE, AND OUTLOOK
Size, Decline, and Outlook underscores the evolving landscape of ranibizumab therapies within ophthalmology. Recent market insights, market trends, and industry trends from our comprehensive Lucentis Market report reveal significant shifts in treatment adoption, pricing strategies, and regional performance. The Lucentis Market size contraction illustrates pricing pressures, while our detailed industry size analysis supports business growth initiatives, guiding expert stakeholders through an in-depth market research framework.
The Global Lucentis Market is estimated to be valued at USD 739.1 Mn in 2025 and is expected to reach USD 64.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -29.5% from 2025 to 2032.
Declining market revenue stems from increased competition from biosimilar ranibizumab and alternative therapies, driving a contraction in market revenue. This forecast underscores shifting market scope and market dynamics, as pricing pressures and evolving reimbursement policies act as key market drivers and restraints. The Lucentis Market report highlights that Asia-Pacific demand, emerging digital treatment platforms, and specialized service models will expand market opportunities in the forecast period.
Key Takeaways
• Market segments: Therapy type, end-user, and distribution channel revealed unique adoption and growth trends in 2025.
• Dominating Region (2025): North America remained the largest market, driven by a 12% increase in clinical adoption across US retinal centers in H1 2025, reflecting robust Lucentis Market Share and high treatment volume.
• Fastest-Growing Region (2025): Asia-Pacific recorded a 5.4% surge in Lucentis prescriptions, bolstered by expanding diabetic retinopathy screening programs in China.
• By Therapy Type – Dominant: Monotherapy held precedence, with Genentech reporting over 200,000 vials sold in 2024. Fastest-Growing: Combination therapy saw a 7% uptake growth in 2025 following a multicenter study in Europe.
• By End-User – Dominant: Hospitals led utilization, exemplified by Singapore General Hospital’s 2025 procurement of 10,000 doses. Fastest-Growing: Ambulatory surgical centers expanded usage by 6% year-on-year.
• By Distribution Channel – Dominant: Hospital pharmacies accounted for majority dispensation volumes in 2024. Fastest-Growing: Retail pharmacies grew 8% in Southeast Asia in 2025, as treatments shifted towards outpatient settings.
Market Key Trends
The foremost trend reshaping the Lucentis Market is the rapid emergence and uptake of biosimilar ranibizumab, which has intensified price competition and altered market dynamics. In October 2024, the US Food and Drug Administration approved the first ranibizumab biosimilar, leading to a 25% average price reduction by Q2 2025, as reported by IMS Health. By mid-2025, biosimilars accounted for nearly 15% of total ranibizumab prescriptions across Europe and North America, prompting a decline in originator market share and eroding Lucentis industry share by approximately 5% in Q4 2024. This regulatory milestone has spurred market players to adjust market growth strategies – including value-based contracting and co-development partnerships – to mitigate revenue erosion. In response, key companies initiated patient support programs and digital adherence tools; for instance, a Genentech collaboration with a telehealth provider in 2025 resulted in a 10% improvement in injection compliance rates. Regulatory incentives in emerging markets like India and Brazil further accelerated biosimilar launches, projecting a compound uptake rate of 18% through 2027. The Lucentis Market trends now center on pricing innovation and expanded access via biosimilar platforms, underlining the importance of adaptive market drivers in a contracting revenue environment.
Key Players
Below is a list of leading market companies operating in the Lucentis Market:
• Genentech, Inc.
• Novartis AG
• Regeneron Pharmaceuticals
• Alcon
• Roche
• AbbVie
• Bayer AG
• Biogen
• Alvotech
• Sandoz
• Apellis Pharmaceuticals
• Iveric Bio
• Bausch + Lomb
• Sun Pharmaceutical Industries
• Pfizer
• Santen Pharmaceutical
Leading market players are proactively implementing growth strategies to counteract the declining Lucentis Market revenue. In 2025, Genentech partnered with a telemedicine provider to launch digital treatment-adherence solutions, resulting in a reported 10% increase in patient retention. Novartis expanded regional manufacturing capacity in Europe during 2024, reducing lead times by 15%, and inked an exclusive distribution agreement with a major Middle Eastern distributor, boosting its market access. Additionally, Alvotech and Biogen co-developed a next-generation biosimilar in early 2025, capturing 8% of the European ranibizumab segment within six months. These strategic partnerships and innovations underscore evolving market dynamics and business growth tactics among market players.
FAQs
1. Who are the dominant players in the Lucentis Market?
Dominant players include Genentech, Inc., Novartis AG, Roche, Regeneron Pharmaceuticals, and Alcon.
2. What will be the size of the Lucentis Market in the coming years?
The market is projected to decline from USD 739.1 Mn in 2025 to USD 64.1 Mn by 2032.
3. Which end-user industry has the largest growth opportunity?
Hospitals led utilization in 2025, while ambulatory surgical centers show fastest growth due to outpatient adoption.
4. How will market development trends evolve over the next five years?
Adoption of biosimilars, digital adherence tools, and value-based contracting will drive future dynamics.
5. What is the nature of the competitive landscape and challenges in the Lucentis Market?
Heightened biosimilar competition, pricing pressures, and reimbursement constraints represent critical market challenges.
6. What go-to-market strategies are commonly adopted in the Lucentis Market?
Key strategies include patient support programs, strategic partnerships, and regional manufacturing expansions.
Read More Articles Related to this Industry –
Fumaric Acid in Industrial Applications: From Resins to Pharmaceuticals
Recent Developments in Active Pharmaceutical Ingredients Industry
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)